PHARMASPIRE - Volume 14, Issue 03 , 2022 , July-September

Pages: 104-108
Print Article   Download XML  Download PDF

COVID-19: Accident or plan

Author: Anuradha Sharma

Category: Pharmaceutics

Abstract:

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. It affected all over the world population to large extent. It becomes the topic of discussion as the accident or plan. In this communication, author tried to cover all the aspects about COVID-19, its history, facts, its symptoms, precautions, treatment, and natural remedies.

Keywords: Coronavirus disease, Precautions, Remedies, Symptoms and treatment

DOI: 10.56933/Pharmaspire.2022.14213

DOI URL: https://doi.org/10.56933/Pharmaspire.2022.14213

References:

1. Nalbandian A, Sehga K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601-15.
2. Pokhrel S, Chhetri R. A literature review on impact of COVID-19 pandemic on teaching and learning. High Educ Future 2021;8:133-41.
3. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol 2021;71:111-6.
4. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC-United States, January 1-April 30, 2021. Morb Mortal Wkly Rep 2021;70:792-3.
5. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York state. N Engl J Med 2022;386:116-27.
6. Thomas SJ, Moreira ED Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021;385:1761-73.
7. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021;5:947-53.
8. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med 2022;386:35-46.
9. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med 2021;27:1338-9.
10. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A randomized clinical trial. JAMA Intern Med 2022;182:115-26.
11. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors associated with COVID-19 vaccine hesitancy. Vaccines 2021;9:300.
12. Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: Neurological complications of COVID?19 vaccines. Ann Neurol 2021;89:856-7.
13. Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines 2021;9:210.
14. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021;385:1172-83.
15. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020;7:11.
16. Lau SK, Chan JF. Coronaviruses: Emerging and re-emerging pathogens in humans and animals. Virol J 2015;12:209.
17. Available from: https://clinicaltrials.gov/ct2/show/study/ NCT04315298?term=sarilumab&draw=2 [Last accessed on 2022 Aug 02].
18. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
19. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55:105932.
20. Osterholm M, Olshaker M. Deadliest Enemy: Our War against Killer Germs. London: Hachette UK; 2020.